Pharma firm Rubicon Research files Rs 1,085 crore IPO with Sebi.

Pharma firm Rubicon Research files for Rs 1,085 crore IPO with Sebi. Fresh issue worth Rs 500 crore and OFS valued at Rs 585 crore by promoter, General Atlantic Singapore RR Pte Ltd. Proceeds to be used for debt repayment, acquisitions, strategic initiatives, and general corporate purposes. Rubicon has two USFDA-inspected R&D facilities and two manufacturing units in India, with a portfolio of 69 USFDA-approved products and 46 in various stages of development.

August 01, 2024
4 Articles

Further Reading